RV 521

Drug Profile

RV 521

Alternative Names: RV-521

Latest Information Update: 19 May 2017

Price : $50

At a glance

  • Originator ReViral
  • Class Antivirals; Small molecules
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Respiratory syncytial virus infections

Most Recent Events

  • 24 Apr 2017 Top-line adverse events and pharmacokinetics data from a phase I trial in Respiratory syncytical virus infections released by ReViral
  • 24 Apr 2017 ReViral plans a phase IIa trial for Respiratory syncytial virus infections in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top